PermeaDerm
PermeaDerm develops FDA-cleared biosynthetic wound matrix products (PermeaDerm-B, -C, -G) for burn, chronic, and surgical wound care, leveraging variable porosity and R.A.S.E. healing technology, commercialized via distribution partners in the US, Europe, and Greater China.
- Company typePrivate
- Founded2013
- HeadquartersCarlsbad, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What PermeaDerm does
PermeaDerm, Inc. is a San Diego-based medical device company that develops and commercializes a family of FDA 510(k)-cleared biosynthetic wound matrix products for the treatment of burns, chronic wounds, and surgical or traumatic wounds. The company's proprietary Biosynthetic Matrix (BSM) Technology combines a silicone membrane epidermal analogue (with variable slits for oxygen, carbon dioxide, and exudate diffusion) and a 3D micro-scaffold dermal analogue with bio-coating, configured with variable porosity to allow customization across wound types. The portfolio consists of three product variants: PermeaDerm-B for acute wounds (partial thickness burns, donor sites, surgical wounds), PermeaDerm-C for chronic wounds (diabetic ulcers, venous ulcers, pressure sores, vascular ulcers), and PermeaDerm-G (gloves) for debrided partial thickness hand burns. The technology operates through an R.A.S.E. mode of action — Reconstruction of skin barrier and ECM, primary Adherence within 5 hours, secondary Adherence (3D structure) within 72 hours, and Epithelialization.
PermeaDerm was founded by Dr. Aubrey Woodroof, the inventor of Biobrane (the first bilaminate biosynthetic temporary wound dressing) and holder of multiple patents covering Biobrane, AWOD, AWOD Plus, and PermeaDerm. The company received FDA 510(k) clearance in 2016 and ISO 13485 certification in 2018. In August 2019, PermeaDerm was acquired by Stedical Scientific (Shanghai) Co., Ltd., with Dr. Woodroof continuing as Chief Scientific Officer. Following the acquisition, Stedical Scientific provides the R&D and manufacturing infrastructure while leveraging top-tier distribution partners in the wound care, infection control, and burn markets for commercialization across the US, Europe, and Greater China. The company is also running multi-center clinical trials in the US and China (184 subjects across 4 Chinese centers) to support expanded regulatory approval and clinical evidence, with stated expansion intent into the Middle East, Southeast Asia, Africa, and Latin America.
The business model is primarily hardware sales of FDA-cleared medical devices through distribution partners, supplemented by clinical trial services in support of regulatory expansion. Pricing is not publicly disclosed. The company reports that thousands of patients have been treated in US burn centers since the 2020 US launch, with a cited clinical outcome of 9-day healing for deep second-degree burns versus a typical 3-7 week healing time. No revenue figures, headcount, or funding rounds are publicly disclosed.
PermeaDerm firmographics
Firmographics- Name
- PermeaDerm
- Legal name
- PermeaDerm, Inc.
- Website
- https://permeaderm.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Acquired
- Headcount range
- 1–10 employees
- Short description
- PermeaDerm develops FDA-cleared biosynthetic wound matrix products (PermeaDerm-B, -C, -G) for burn, chronic, and surgical wound care, leveraging variable porosity and R.A.S.E. healing technology, commercialized via distribution partners in the US, Europe, and Greater China.
- Ownership category
- akta.pro rank
PermeaDerm industry classification
Industry- Product category
- Biosynthetic Wound Care Medical Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)
- akta.pro secondary industries
- Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG), Wound Care & Ulcer Management (HLAKACAN), Wound Care & Diabetic Foot Infection (HLAKAGAK), Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film) (HLAHALAA), Burn Care Specialty Hospitals (HLAFAHAF)
Keywords
Where PermeaDerm is headquartered
LocationHeadquarters
- HQ city
- Carlsbad
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
PermeaDerm business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
Revenue model
- PermeaDerm Product Sales: Revenue generated from sale of FDA-cleared PermeaDerm medical device products (PermeaDerm-B, -C, and -G) for burns, diabetic ulcers and chronic wounds. Products commercialized in U.S., Europe and Greater China markets through distribution partnerships.
- Clinical Trial Services: Multi-center clinical studies conducted in China (184 subjects across 4 centers) and United States for regulatory approval expansion and clinical evidence generation.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels4 records
PermeaDerm product offering
Product offeringCore offering
PermeaDerm develops and manufactures FDA-cleared 510(k) biosynthetic wound matrix products for the treatment of burns, diabetic ulcers, and chronic wounds. The product family includes PermeaDerm-B for acute wounds, PermeaDerm-C for chronic wounds, and PermeaDerm-G gloves for hand burns, all based on a proprietary Biosynthetic Matrix (BSM) technology featuring variable porosity and a 3D micro-scaffold structure.
Product overview
PermeaDerm is a family of FDA-cleared 510(k) biosynthetic wound matrix products developed by Stedical Scientific following its 2019 acquisition of PermeaDerm, Inc. The portfolio consists of PermeaDerm-B for acute wounds, PermeaDerm-C for chronic wounds, and PermeaDerm-G for hand burn treatment. All products are based on a proprietary Biosynthetic Matrix (BSM) Technology featuring a silicone membrane epidermal analogue and 3D micro-scaffold dermal analogue that creates an optimal moist wound healing environment through the R.A.S.E. (Reconstruction, Adherence, Secondary adherence, Epithelialization) mode of action.
Differentiator
Problem solved
Functional benefit
Brands
- PermeaDerm® Biosynthetic Wound Matrix: Biosynthetic matrix technology for wound management of chronic wounds and burns, including PermeaDerm B (acute wounds), PermeaDerm C (chronic wounds), and PermeaDerm G (hand burn gloves)
- PermeaDerm Gloves
- PermeaDerm-B
- PermeaDerm-C
Products and services
- PermeaDerm® Biosynthetic Wound Matrix FDA-cleared 510(k) biosynthetic wound matrix medical device combining an epidermal analogue (silicone membrane with variable slits) and dermal analogue (3D micro-scaffold with bio-coating) to create a moist healing environment. Uses R.A.S.E. mode of action: Reconstruction of skin barrier and ECM, Primary Adherence, Secondary Adherence, and Epithelialization. For healthcare providers treating burn and chronic wound patients.
- PermeaDerm-B FDA-cleared 510(k) medical device variant for acute wounds including partial thickness burns, donor sites, coverage of meshed autograft, surgical wounds, abrasions, lacerations, and skin tears.
- PermeaDerm-C FDA-cleared 510(k) medical device variant for chronic wounds including pressure sores, venous ulcers, diabetic ulcers, and vascular ulcers.
- PermeaDerm-G (Gloves) FDA-cleared 510(k) medical device specifically designed as gloves for treatment of debrided partial thickness hand burns and other partial thickness hand wounds.
Quantifiable outcome
- Deep second-degree burns healed in 9 days with single application, compared to typical 3-7 week healing time
- +3 more outcomes
Companies that use PermeaDerm
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
PermeaDerm technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
PermeaDerm partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- American Burn AssociationcoreStedical announced Burn Clinical Trial enrollment at the ABA Townhall meeting during the 54th American Burn Association annual meeting in Las Vegas, April 5-8, 2022.
- Shanghai Changhai HospitalcoreKey clinical research partner for PermeaDerm clinical trials in China. Led by China National Engineering Academician Dr. Zhaofan Xia. Stedical initiated first discussion with this hospital in 2019 regarding clinical development of PermeaDerm technology in China.
- Wuxi Affiliated Hospital of Jiangnan UniversitycoreClinical trial partner led by Dr. Guozhong Lv, Chairman of China Burn Association. Participated in Clinical Trial Investigator Symposium and contributes to study design.
- Shanghai Ruijin HospitalcoreClinical trial partner led by Dr. Yan Liu, Vice Chairman of China Burn Association. Participated in multi-center clinical study design and implementation.
- Tongren Hospital (Wuhan University)coreClinical trial partner led by Dr. Weiguo Xie, Director of Burn Department and past Vice President of China Burn Association. Contributed to clinical trial design.
- Dr. David HerndoncoreMember of US National Academy of Medicine, Editor of Journal of Burn Care and Research, and Chairman of Scientific Advisory Committee at Stedical Scientific in both China and the U.S. Joined via video conference to symposium, providing historical context and endorsement of PermeaDerm technology.
- Jones DayminorJones Day acted as legal counsel to Stedical Scientific in the United States for the acquisition of PermeaDerm, Inc.
- King & Wood MallesonsminorKing & Wood Mallesons acted as legal counsel to Stedical Scientific in China for the acquisition transaction.
Scale indicators8 records
Recent moves7 records
Expansion highlights6 records
PermeaDerm competitors and assessment
Company assessmentDirect peers
- Organogenesis: Organogenesis markets Apligraf and Dermagraft, leading living-cell skin substitutes for chronic wounds and burns. It competes head-to-head with PermeaDerm in advanced wound care across diabetic foot ulcers, venous ulcers, and burn coverage.
- MiMedx: MiMedx sells dehydrated amniotic membrane allografts (EpiFix, AmnioFix) used as skin substitutes for chronic wounds and surgical applications. It is a directly competing skin-substitute platform targeting the same burn and chronic-wound call points.
- Integra LifeSciences: Integra LifeSciences manufactures Integra Dermal Regeneration Template and other skin-substitute / regenerative wound-care products. It is the most direct competitor to PermeaDerm in the biosynthetic and biologic skin-substitute category for burns and chronic wounds.
Emerging players
- Avita Medical: Avita Medical sells the RECELL system, an autologous cell-harvesting platform for burns and wound treatment. It targets the same burn-center customers as PermeaDerm with a differentiated point-of-care cell therapy approach.
- Aroa Biosurgery: Aroa Biosurgery develops ovine forestomach-derived extracellular matrix wound products (Endoform, Myriad) for chronic and surgical wounds. It is an emerging skin-substitute and regenerative wound-care peer with similar hospital-segment targeting.
- Vericel: Vericel markets Epicel (cultured epidermal autografts) for severe burns. It competes with PermeaDerm-G in deep and hand-burn treatment, particularly in US burn centers where adoption decisions are made.
Broad incumbents
- Coloplast: Coloplast provides wound-care and skin-care dressings (Biatain, etc.) used for chronic wounds and burns. It is a broad incumbent in advanced wound care with established distribution channels overlapping PermeaDerm's targets.
- Smith+Nephew: Smith+Nephew is a global wound-care leader whose Advanced Wound Management portfolio (including ALLEVYN, DURAFIBER, and historically Biobrane) overlaps with PermeaDerm's burn and chronic-wound use cases. As the original commercializer of Biobrane, it is the benchmark PermeaDerm explicitly aims to surpass.
- Mölnlycke Health Care: Mölnlycke provides Mepilex, Mepitel, and other advanced wound dressings used across burns and chronic wounds globally. It competes with PermeaDerm as a broad incumbent with established hospital contracts and international distribution.
- ConvaTec: ConvaTec offers AQUACEL and other advanced wound-care products for chronic wounds and burns. Its portfolio overlaps PermeaDerm's chronic-wound segment (diabetic, venous, pressure ulcers) and competes in the same hospital formularies.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
PermeaDerm social profiles
Digital presencePermeaDerm compliance and trust
Trust signalCompliance2 records
PermeaDerm financial estimates
Financial estimateRevenue estimate
Valuation estimate
PermeaDerm leadership team
Management profileNumber of profiles
Profiles3 records
PermeaDerm funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PermeaDerm M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PermeaDerm
What does PermeaDerm do?
PermeaDerm develops and manufactures FDA-cleared 510(k) biosynthetic wound matrix products for the treatment of burns, diabetic ulcers, and chronic wounds. The product family includes PermeaDerm-B for acute wounds, PermeaDerm-C for chronic wounds, and PermeaDerm-G gloves for hand burns, all based on a proprietary Biosynthetic Matrix (BSM) technology featuring variable porosity and a 3D micro-scaffold structure.
Is PermeaDerm a public or private company?
PermeaDerm is a private company. It is classified as corporate owned and is currently acquired.
When was PermeaDerm founded?
PermeaDerm was founded in 2013. It employs 1 to 10 people.
Where is PermeaDerm based?
PermeaDerm is headquartered in Carlsbad, United States, in the North America region.
How does PermeaDerm make money?
Two revenue lines are on record. PermeaDerm Product Sales are the primary driver. The others are clinical Trial Services.
Who are PermeaDerm's main competitors?
Direct peers on record are Organogenesis, MiMedx and Integra LifeSciences. Emerging players are Avita Medical, Aroa Biosurgery and Vericel. Broad incumbents are Coloplast, Smith+Nephew, Mölnlycke Health Care and ConvaTec.
Does PermeaDerm have an API?
No public API is recorded for PermeaDerm.
What industry is PermeaDerm in?
PermeaDerm's product category is Biosynthetic Wound Care Medical Devices. Its primary akta.pro industry code is HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts), with a secondary code of HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes). Its NAICS code is 339113 and its SIC code is 3842.